Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis.

Wilson ME, Boumaza I, Lacomis D, Bowser R.

PLoS One. 2010 Dec 9;5(12):e15133. doi: 10.1371/journal.pone.0015133.

2.

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, Lacomis D, Cudkowicz M, Bowser R.

Muscle Nerve. 2010 Jul;42(1):104-11. doi: 10.1002/mus.21683.

3.

Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Ren Y, Zhu W, Cui F, Yang F, Chen Z, Ling L, Huang X.

Int J Clin Exp Pathol. 2015 May 1;8(5):5419-26. eCollection 2015.

4.

Cystatin C in cerebrospinal fluid as a biomarker of ALS.

Tsuji-Akimoto S, Yabe I, Niino M, Kikuchi S, Sasaki H.

Neurosci Lett. 2009 Mar 6;452(1):52-5.

PMID:
19444952
5.

Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.

Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR.

JAMA Neurol. 2013 Dec;70(12):1505-11. doi: 10.1001/jamaneurol.2013.4646.

PMID:
24145899
6.

Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.

Boylan KB, Glass JD, Crook JE, Yang C, Thomas CS, Desaro P, Johnston A, Overstreet K, Kelly C, Polak M, Shaw G.

J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):467-72. doi: 10.1136/jnnp-2012-303768. Epub 2012 Oct 31.

PMID:
23117489
7.

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.

Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH Jr, Bowser R.

J Neurochem. 2005 Dec;95(5):1461-71.

8.

CSF glial markers correlate with survival in amyotrophic lateral sclerosis.

Süssmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, Ludolph AC, Tumani H.

Neurology. 2010 Mar 23;74(12):982-7. doi: 10.1212/WNL.0b013e3181d5dc3b.

PMID:
20308682
9.

Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.

Chen X, Chen Y, Wei Q, Ou R, Cao B, Zhao B, Shang HF.

BMC Neurol. 2016 Sep 15;16:173. doi: 10.1186/s12883-016-0689-x.

10.

Utility of cystatin C for renal function in amyotrophic lateral sclerosis.

Tetsuka S, Morita M, Ikeguchi K, Nakano I.

Acta Neurol Scand. 2013 Dec;128(6):386-90. doi: 10.1111/ane.12134. Epub 2013 Jun 27.

PMID:
23802939
11.

Identification of potential CSF biomarkers in ALS.

Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L.

Neurology. 2006 Apr 25;66(8):1218-22. Epub 2006 Feb 15.

PMID:
16481598
12.

Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis.

Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M.

Neurobiol Aging. 2015 Feb;36(2):1072-4. doi: 10.1016/j.neurobiolaging.2014.10.019. Epub 2014 Oct 18.

PMID:
25453560
13.

Elevated Levels of IFN-γ in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis.

Liu J, Gao L, Zang D.

PLoS One. 2015 Sep 2;10(9):e0136937. doi: 10.1371/journal.pone.0136937. eCollection 2015.

14.

A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.

Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR.

Neurology. 2009 Jan 6;72(1):14-9. doi: 10.1212/01.wnl.0000333251.36681.a5. Epub 2008 Nov 5.

PMID:
18987350
15.

Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.

Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R.

J Neurochem. 2011 May;117(3):528-37. doi: 10.1111/j.1471-4159.2011.07224.x. Epub 2011 Mar 21.

16.

Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis.

Gonçalves M, Tillack L, de Carvalho M, Pinto S, Conradt HS, Costa J.

Clin Chim Acta. 2015 Jan 1;438:342-9. doi: 10.1016/j.cca.2014.09.011. Epub 2014 Sep 28.

PMID:
25261856
17.

Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Kolarcik C, Bowser R.

Mol Diagn Ther. 2006;10(5):281-92. Review.

PMID:
17022691
18.

Measurement of cystatin C functional activity in the cerebrospinal fluid of amyotrophic lateral sclerosis and control subjects.

Wilson ME, Boumaza I, Bowser R.

Fluids Barriers CNS. 2013 Mar 15;10(1):15. doi: 10.1186/2045-8118-10-15.

19.

Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis.

Lehnert S, Costa J, de Carvalho M, Kirby J, Kuzma-Kozakiewicz M, Morelli C, Robberecht W, Shaw P, Silani V, Steinacker P, Tumani H, Van Damme P, Ludolph A, Otto M.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):344-50. doi: 10.3109/21678421.2014.884592. Epub 2014 Feb 28.

PMID:
24575871
20.

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A.

Neurology. 2015 Jun 2;84(22):2247-57. doi: 10.1212/WNL.0000000000001642. Epub 2015 May 1. Erratum in: Neurology. 2015 Sep 8;85(10):921.

Supplemental Content

Support Center